Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients
Journal of Clinical Rheumatology (JCR), 10/08/09

Shefali M et al. – Early uncontrolled clinical experience indicates that rituximab may be a valuable therapeutic agent for treatment of refractory IIM. Further investigation regarding the optimal dosing regimen, treatment length, and long-term safety profile of rituximab therapy for IIM is warranted.

Methods

Describe the clinical courses of 3 patients with IIM treated with rituximab after unsatisfactory responses to conventional therapy
Performed search of English language literature utilizing PubMed, and identified 8 articles that also described use of rituximab for treatment of IIM

Results

Improvement in patients was manifested by increase in muscle strength and decline in creatinine kinase levels in all 3 patients
Recurrent muscle weakness and elevated muscle enzymes occurred in 2 patients postinfusion; retreatment with rituximab resulted in similar clinical improvement
Our experience, and that 20 of 21 patients described in 8 cited reports demonstrate a favorable clinical response in patients treated with B-cell depletion therapy for II

<< Previous
Switching to the anti-interleukin-6 receptor antibody tocilizumab...

Next >>
The IL-1-like cytokine IL-33 and its receptor ST2 are abnormally...